StockData

Caribou Biosciences vs CRISPR Therapeutics

CRBU and CRSP side by side, both in drugs. Figures are trailing twelve months unless noted, from SEC filings and end-of-day prices.

How CRBU and CRSP compare

CRISPR Therapeutics is the larger company, worth 106 times as much as Caribou Biosciences ($3.9B against $36.5M).

Caribou Biosciences grew revenue faster over the last twelve months (10.0% versus −64.8% for CRISPR Therapeutics).

Caribou Biosciences keeps more of each dollar of sales as profit, with a net margin of −1030% compared with −3369% at CRISPR Therapeutics.

Caribou Biosciences scores higher on the StockData Score (9 against 8 for CRISPR Therapeutics), which adds up 30 checks on valuation, growth, past performance, financial health and dividends.

Key numbers

A dot marks the better figure where higher or lower is clearly better.

MetricCRBUCRSP
Size and price
Market cap$36.5M$3.9B
Share price$0.341$40.15
Change, 1 year−82.9%−23.6%
Change, 5 years−98.1%−49.0%
Beta (5Y)1.411.59
Employees97393
StockData Score
Total score9 (better)8
Valuation score3 (better)0
Growth score11
Performance score02 (better)
Health score55
Dividend score00
Valuation
P/S3.6× (better)290×
P/B0.4× (better)2.2×
FCF yield−262%−9.6% (better)
Fair value$1.29–
Margin of safety73.7%–
Growth
Revenue growth (TTM)10.0% (better)−64.8%
Revenue growth, 5Y average−2.0%37.3% (better)
Profitability
Operating margin−1091% (better)−3990%
Net margin−1030% (better)−3369%
FCF margin−954% (better)−2773%
Return on equity−78.3%−26.1% (better)
Financial health
Debt / equity0.000.00
Current ratio6.4917.85 (better)
Altman Z-score−7.471.79 (better)
Piotroski F-score22
Dividends and buybacks
Buyback yield−66.3%−10.0% (better)
Shareholder yield−66.3%−10.0% (better)
Ownership
Held by institutions45.5%78.9%
Held by insiders5.7%2.7%
Insider net buying, 12 months−$47.5K (better)−$17.9M
Short interest, % of float14.7%18.3%

Go deeper

For information only, not investment advice. Check the source filings before relying on any figure.